Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study
Molecules · 2025-07-16 · 30 (14) · 2995
DOI: 10.3390/molecules30142995 ↗At a glance
Validierungsstudie in Molecules, published online on 2025-07-16. Written by Yuna Song and 7 co-authors. Institution: Department of Biomedical and Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic o…. Major MEDLINE topics: Sitagliptin Phosphate, Tandem Mass Spectrometry, Dipeptidyl-Peptidase IV Inhibitors. Cited 4 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Korea Health Technology R&D Project, Ministry of Food and Drug Safety.
Abstract (original language)
Sitagliptin is an orally bioavailable selective DPP4 inhibitor that reduces blood glucose levels without significant increases in hypoglycemia. The aim of this study was to design and validate an innovative, rapid, and highly sensitive LC–MS/MS assay for the precise measurement of sitagliptin concentrations in human plasma. This analytical method, utilizing sitagliptin-d4 as the internal standard, is performed using only 100 μL of plasma and a liquid–liquid extraction procedure based on methyl tert-butyl ether (MTBE). Chromatographic separation is expertly achieved with a Kinetex® C18 column under isocratic elution, employing a perfect 1:1 blend of 5 mM ammonium acetate (with 0.04% formic acid) and acetonitrile, and maintaining an efficient flow rate of 0.2 mL/min. Detection occurs in positive ionization mode through multiple reaction monitoring, precisely targeting transitions of m/z 408.2 → 193.0 for sitagliptin and 412.2 → 239.1 for the IS. The total runtime of this assay is under 2 min. Comprehensive validation in line with MFDS and FDA criteria demonstrates outstanding linearity (5–1000 ng/mL, r2 > 0.998), alongside impressive levels of accuracy, precision, recovery and sample stability. Due to its minimal sample requirement and high-throughput capability, the validated approach is highly appropriate for pharmacokinetic and bioequivalence assessments involving sitagliptin.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical and Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea.
- Kyung Hee Drug Analysis Center, College of Pharmacy, Kyung Hee University, 26, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, 23, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea.
- Department of Pharmacy, College of Pharmacy, Kyung Hee University, 26, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea.
ORCID profiles: Yuna Song, Wang-Seob Shim, Eunseo Song, Bo-Hyung Kim, Eun Kyoung Chung, Kyung-Tae Lee
Funding
- Korea Health Technology R&D Project
- Ministry of Food and Drug Safety
Cite
APA
Song, Y., Shim, W. S., Song, E., Park, Y., Kim, B. H., Lee, S., Chung, E. K., & Lee, K. T. (2025). Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study. Molecules, 30(14), 2995. https://doi.org/10.3390/molecules30142995
Vancouver
Song Y, Shim WS, Song E, Park Y, Kim BH, Lee S, et al. Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study. Molecules. 2025;30(14):2995. doi:10.3390/molecules30142995
BibTeX
@article{Song2025,
author = {Song, Yuna and Shim, Wang-Seob and Song, Eunseo and Park, Yebeen and Kim, Bo-Hyung and Lee, Sangmin and Chung, Eun Kyoung and Lee, Kyung-Tae},
title = {Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study},
journal = {Molecules},
year = {2025},
volume = {30},
number = {14},
pages = {2995},
doi = {10.3390/molecules30142995}
}
EUVIMED